Accelerating Patent Timelines: From Four Years to One in Biotech and Pharma with Josh Goldberg

The best biotech and pharmaceutical innovations mean nothing if they can't be protected—and protected fast. 

Our next guest, Josh Goldberg, is solving this challenge as co-managing partner at Nath, Goldberg & Meyer, the #1 ranked patent law firm for biotech and pharmaceutical technologies. 

With nearly three decades of IP law experience and a unique background as a lab researcher, Josh brings an insider's understanding of how innovation actually happens. 

He's helped industry leaders like Amgen, Takeda, and GlaxoSmithKline turn breakthrough treatments into patent-protected portfolios—often in under a year instead of the typical four-year timeline. 

Driven by a passion for focus and strategic IP timing, Josh shares his pioneering approach to biotech and pharmaceutical patent prosecution. 

Join us to discover how smart IP strategy drives licensing power, regulatory success, and company valuation. Let's go!

Episode Highlights:

• Focus drives success – Companies fail by trying to do everything at once; staying deliberate and focused is key to making real impact
• One-year patent timelines vs. four years – Josh uses USPTO's Track 1 program to secure patents in record time, improving fundraising and M&A positioning
• Client-centered approach wins – Listening to unique client needs instead of one-size-fits-all strategies earned the firm its #1 ranking
• Diagnostic patents are back – New USPTO Director signals the patent office is "open for business" again after a decade of restrictions
• Scientist turned patent attorney – Josh's lab background gives him insider understanding of how innovation actually happens

About our Guest: 

Joshua is the patent attorney innovation-driven pharmaceutical companies call when they need to turn complicated technologies into protected assets in record time.

As co-managing partner at Nath, Goldberg & Meyer—the #1 ranked patent law firm for biotech and pharmaceutical technologies in both 2024 and 2025—Joshua leads IP efforts across industries like biotech, pharma, agriculture, renewable energy, and advanced materials. 

Whether it’s a blockbuster acne treatment like DUAC, a vitamin D analog lotion like Sorilux, OTC solutions like Salonpas and Germagic, or a leading drug used to reduce stomach acid and treat conditions like GERD, ulcers, and heartburn—like Protonix—Joshua helps turn high-stakes R&D into patent-protected portfolios, often in under a year instead of the typical four-year timeline.

Though his climate and agricultre IP expertise has made him famous as the “green patent guy,” Joshua moves between disciplines skillfully and has helped industry leaders like Amgen, Takeda, Guilford Pharmaceuticals, Mayne, and Stiefel Laboratories (which was acquired by GlaxoSmithKline) build pharma portfolios that hold up under investor, acquirer, and FDA scrutiny.

His journey didn’t begin in IP law, but in the lab, researching experimental pharmaceutical delivery systems. It gave him an edge most attorneys don’t have: understanding how innovation actually happens, and how to protect it without slowing a business down. 

Links Supporting This Episode: 

• Nath, Goldberg & Meyer Website: CLICK HERE
• Joshua Goldberg LinkedIn page: CLICK HERE
• Nath, Goldberg & Meyer LinkedIn: CLICK HERE
• Mike Biselli LinkedIn page: CLICK HERE
• Mike Biselli Twitter page:...